Header Logo

Katherine Griem

Concepts (153)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
18
2017
414
2.120
Why?
Brachytherapy
10
2017
56
1.480
Why?
Radiation Injuries
3
2012
32
1.090
Why?
Radiotherapy Planning, Computer-Assisted
5
2017
68
0.940
Why?
Radiotherapy, Conformal
5
2011
21
0.930
Why?
Skin
2
2012
116
0.760
Why?
Mastectomy, Segmental
8
2009
31
0.680
Why?
Radiotherapy Dosage
14
2017
117
0.520
Why?
Radiotherapy, Adjuvant
5
2017
52
0.470
Why?
Radiometry
4
2017
41
0.450
Why?
Carcinoma, Ductal, Breast
4
2008
34
0.430
Why?
Prone Position
2
2011
36
0.420
Why?
Thermal Conductivity
1
2012
3
0.410
Why?
Thermography
1
2012
14
0.410
Why?
Radiotherapy, Intensity-Modulated
2
2009
38
0.390
Why?
Lymph Nodes
2
2011
70
0.390
Why?
Breast
3
2010
24
0.370
Why?
Combined Modality Therapy
12
2010
306
0.340
Why?
Genital Neoplasms, Female
1
2010
14
0.340
Why?
Heart
2
2009
66
0.340
Why?
Axilla
2
2008
13
0.330
Why?
Taxoids
1
2009
10
0.330
Why?
Radiodermatitis
1
2009
4
0.330
Why?
Female
25
2012
15777
0.320
Why?
Antineoplastic Agents
2
2009
190
0.310
Why?
Middle Aged
18
2011
9316
0.240
Why?
Humans
31
2017
28449
0.240
Why?
Posture
1
2003
68
0.220
Why?
Head and Neck Neoplasms
4
1997
151
0.200
Why?
Carcinoma, Squamous Cell
4
1997
177
0.190
Why?
Adult
17
2011
8155
0.190
Why?
Feasibility Studies
3
2011
234
0.180
Why?
Aged
15
2011
9320
0.180
Why?
Intraoperative Care
2
2017
43
0.160
Why?
Lymph Node Excision
2
1996
27
0.160
Why?
Supine Position
2
2011
21
0.150
Why?
Radiography
4
2009
652
0.150
Why?
Mice
2
2012
1475
0.150
Why?
Treatment Failure
2
2008
163
0.140
Why?
Retrospective Studies
7
2013
3615
0.130
Why?
Lung
3
2011
169
0.130
Why?
Neoplasm Staging
4
2010
372
0.130
Why?
Animals
2
2012
3808
0.110
Why?
Accreditation
1
2013
14
0.110
Why?
Radiation Oncology
1
2013
14
0.110
Why?
Imaging, Three-Dimensional
2
2006
235
0.110
Why?
Pilot Projects
3
2012
441
0.100
Why?
Mice, Hairless
1
2012
3
0.100
Why?
Body Water
1
2012
4
0.100
Why?
Tomography
1
2012
13
0.100
Why?
Education, Medical, Graduate
1
2013
77
0.100
Why?
Fluorouracil
5
1999
46
0.100
Why?
Physicians
1
2013
121
0.090
Why?
Iridium Radioisotopes
2
2008
4
0.090
Why?
Electronics
2
2010
11
0.090
Why?
Logistic Models
1
2012
399
0.090
Why?
Monte Carlo Method
2
2017
53
0.090
Why?
Clinical Competence
1
2013
243
0.090
Why?
Antineoplastic Combined Chemotherapy Protocols
6
1997
244
0.090
Why?
Disease-Free Survival
3
2007
177
0.090
Why?
Internship and Residency
1
2013
215
0.080
Why?
Neoplasm Recurrence, Local
6
1996
206
0.080
Why?
Radioisotope Teletherapy
1
1989
1
0.080
Why?
Treatment Outcome
6
2010
3619
0.080
Why?
Contracture
1
2009
14
0.080
Why?
Cisplatin
4
1997
53
0.080
Why?
Neoplasms, Radiation-Induced
1
1989
12
0.080
Why?
Organ Size
1
2009
108
0.080
Why?
Liposarcoma
1
1989
17
0.080
Why?
Biomarkers
1
2012
594
0.080
Why?
Lymphatic Metastasis
2
2008
91
0.080
Why?
Thyroid Neoplasms
1
1989
46
0.080
Why?
Rectal Neoplasms
1
1989
14
0.080
Why?
Heart Ventricles
1
2009
102
0.080
Why?
Carcinoma, Lobular
2
2007
21
0.080
Why?
Follow-Up Studies
7
2010
1870
0.080
Why?
Models, Biological
2
2004
329
0.080
Why?
Carcinoma in Situ
1
2007
10
0.070
Why?
Mastectomy
1
1987
37
0.070
Why?
Aged, 80 and over
5
2009
4881
0.070
Why?
Tomography, X-Ray Computed
3
2007
772
0.070
Why?
Cell Division
2
1996
83
0.060
Why?
Electrons
1
2004
18
0.060
Why?
Reference Values
1
2003
199
0.050
Why?
Chemotherapy, Adjuvant
3
1996
81
0.050
Why?
Time Factors
4
1996
1499
0.040
Why?
S Phase
2
1996
10
0.040
Why?
Antimetabolites, Antineoplastic
1
1999
17
0.040
Why?
Tongue Neoplasms
1
1999
19
0.040
Why?
Ventricular Dysfunction, Left
1
1999
43
0.040
Why?
Carcinoma
1
1999
70
0.040
Why?
Antineoplastic Agents, Hormonal
2
1996
18
0.040
Why?
Tamoxifen
2
1996
29
0.040
Why?
Biopsy
2
1996
221
0.040
Why?
Neoplasm Invasiveness
2
1995
89
0.040
Why?
Water
1
2017
33
0.040
Why?
Dose-Response Relationship, Radiation
2
2007
10
0.030
Why?
Mouth Mucosa
1
1996
13
0.030
Why?
Paclitaxel
1
1996
44
0.030
Why?
Cell Count
1
1996
80
0.030
Why?
Cellulitis
1
1996
10
0.030
Why?
Esophageal Neoplasms
1
1997
54
0.030
Why?
Adenocarcinoma
1
1997
146
0.030
Why?
Immunohistochemistry
1
1996
364
0.030
Why?
Apoptosis
1
1996
205
0.030
Why?
Cell Cycle
1
1995
34
0.030
Why?
Male
7
1999
15352
0.030
Why?
Survival Rate
1
1995
356
0.030
Why?
Neoplasms, Second Primary
1
1994
40
0.030
Why?
Postoperative Care
2
1996
140
0.030
Why?
Hodgkin Disease
1
1993
18
0.030
Why?
Age Factors
1
1995
796
0.030
Why?
Safety
1
2010
44
0.020
Why?
Cobalt Radioisotopes
1
1989
3
0.020
Why?
Nasopharyngeal Neoplasms
1
1989
3
0.020
Why?
Anal Canal
1
1989
3
0.020
Why?
Child
2
1993
1424
0.020
Why?
Preoperative Care
1
1989
125
0.020
Why?
Statistics as Topic
1
1987
116
0.020
Why?
Hemibody Irradiation
1
2007
2
0.020
Why?
Random Allocation
1
1987
129
0.020
Why?
Tumor Burden
1
2007
28
0.020
Why?
United States
1
2013
2185
0.020
Why?
Survival Analysis
2
1997
268
0.020
Why?
Clinical Trials as Topic
1
1987
236
0.020
Why?
Equipment Design
1
2006
154
0.020
Why?
Relative Biological Effectiveness
1
2004
5
0.010
Why?
Body Burden
1
2004
7
0.010
Why?
Particle Accelerators
1
2004
7
0.010
Why?
Scattering, Radiation
1
2004
37
0.010
Why?
Models, Statistical
1
2004
128
0.010
Why?
Actuarial Analysis
2
1995
8
0.010
Why?
Computer Simulation
1
2004
204
0.010
Why?
Risk Factors
1
1989
2414
0.010
Why?
Heart Diseases
1
1999
68
0.010
Why?
Infusions, Intravenous
1
1997
53
0.010
Why?
Esophagectomy
1
1997
24
0.010
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1996
12
0.010
Why?
Anti-Inflammatory Agents
1
1996
80
0.010
Why?
Idoxuridine
1
1995
2
0.010
Why?
Mitotic Index
1
1995
5
0.010
Why?
G2 Phase
1
1995
4
0.010
Why?
Bromodeoxyuridine
1
1995
10
0.010
Why?
DNA, Neoplasm
1
1995
20
0.010
Why?
Recurrence
1
1996
320
0.010
Why?
Lymphoma
1
1995
38
0.010
Why?
Kinetics
1
1995
185
0.010
Why?
Regression Analysis
1
1995
267
0.010
Why?
Proportional Hazards Models
1
1995
354
0.010
Why?
Contraindications
1
1994
33
0.010
Why?
Anti-Bacterial Agents
1
1996
376
0.010
Why?
Postoperative Complications
1
1996
935
0.010
Why?
Adolescent
1
1993
2324
0.000
Why?
Griem's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (153)
Explore
_
Co-Authors (10)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_